Nivolumab in the treatment of advanced renal cell carcinoma

Malmaruha Arasaratnam, Howard Gurney

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Renal cell carcinoma (RCC) has typically been considered an immunogenic malignancy with responses seen to IL-2 and IFN-α. Response rates, however, were low and at the cost of considerable toxicity and as such, agents targeting angiogenesis have become the mainstay of treatment. Nivolumab is an immune checkpoint inhibitor targeting PD-1 thereby upregulating the host immune response against tumor cells. Nivolumab has emerged as a promising new therapy in advanced malignancies, and the first agent to show survival advantage in patients failing prior VEGFR-targeted therapy in metastatic RCC. This review summarizes the present evidence, toxicity profile, potential predictive biomarkers and promising future strategies with nivolumab in metastatic RCC.
LanguageEnglish
Article number 29460635
Pages1679-1689
Number of pages11
JournalFuture Oncology
Volume14
Issue number17
Early online date20 Feb 2018
DOIs
Publication statusPublished - Jul 2018

Fingerprint

Renal Cell Carcinoma
Neoplasms
Interleukin-2
Therapeutics
Biomarkers
Survival
nivolumab

Keywords

  • immunotherapy
  • nivolumab
  • PD-1
  • renal cell carcinoma

Cite this

Arasaratnam, Malmaruha ; Gurney, Howard. / Nivolumab in the treatment of advanced renal cell carcinoma. In: Future Oncology. 2018 ; Vol. 14, No. 17. pp. 1679-1689.
@article{3656791bcbc54dddb2464b7b7957afc2,
title = "Nivolumab in the treatment of advanced renal cell carcinoma",
abstract = "Renal cell carcinoma (RCC) has typically been considered an immunogenic malignancy with responses seen to IL-2 and IFN-α. Response rates, however, were low and at the cost of considerable toxicity and as such, agents targeting angiogenesis have become the mainstay of treatment. Nivolumab is an immune checkpoint inhibitor targeting PD-1 thereby upregulating the host immune response against tumor cells. Nivolumab has emerged as a promising new therapy in advanced malignancies, and the first agent to show survival advantage in patients failing prior VEGFR-targeted therapy in metastatic RCC. This review summarizes the present evidence, toxicity profile, potential predictive biomarkers and promising future strategies with nivolumab in metastatic RCC.",
keywords = "immunotherapy, nivolumab, PD-1, renal cell carcinoma",
author = "Malmaruha Arasaratnam and Howard Gurney",
year = "2018",
month = "7",
doi = "10.2217/fon-2017-0533",
language = "English",
volume = "14",
pages = "1679--1689",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine",
number = "17",

}

Nivolumab in the treatment of advanced renal cell carcinoma. / Arasaratnam, Malmaruha; Gurney, Howard.

In: Future Oncology, Vol. 14, No. 17, 29460635, 07.2018, p. 1679-1689.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Nivolumab in the treatment of advanced renal cell carcinoma

AU - Arasaratnam, Malmaruha

AU - Gurney, Howard

PY - 2018/7

Y1 - 2018/7

N2 - Renal cell carcinoma (RCC) has typically been considered an immunogenic malignancy with responses seen to IL-2 and IFN-α. Response rates, however, were low and at the cost of considerable toxicity and as such, agents targeting angiogenesis have become the mainstay of treatment. Nivolumab is an immune checkpoint inhibitor targeting PD-1 thereby upregulating the host immune response against tumor cells. Nivolumab has emerged as a promising new therapy in advanced malignancies, and the first agent to show survival advantage in patients failing prior VEGFR-targeted therapy in metastatic RCC. This review summarizes the present evidence, toxicity profile, potential predictive biomarkers and promising future strategies with nivolumab in metastatic RCC.

AB - Renal cell carcinoma (RCC) has typically been considered an immunogenic malignancy with responses seen to IL-2 and IFN-α. Response rates, however, were low and at the cost of considerable toxicity and as such, agents targeting angiogenesis have become the mainstay of treatment. Nivolumab is an immune checkpoint inhibitor targeting PD-1 thereby upregulating the host immune response against tumor cells. Nivolumab has emerged as a promising new therapy in advanced malignancies, and the first agent to show survival advantage in patients failing prior VEGFR-targeted therapy in metastatic RCC. This review summarizes the present evidence, toxicity profile, potential predictive biomarkers and promising future strategies with nivolumab in metastatic RCC.

KW - immunotherapy

KW - nivolumab

KW - PD-1

KW - renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85050024303&partnerID=8YFLogxK

U2 - 10.2217/fon-2017-0533

DO - 10.2217/fon-2017-0533

M3 - Article

VL - 14

SP - 1679

EP - 1689

JO - Future Oncology

T2 - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 17

M1 - 29460635

ER -